Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $10.75 (10.42% downside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/19/2015Leerink SwannSet Price TargetBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
3/4/2015Leerink SwannBoost Price TargetOutperform$9.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
1/9/2015Janney Montgomery ScottInitiated CoverageBuy -> NeutralViewTweet This Rating  Share This Rating on StockTwits
11/17/2014JPMorgan Chase & Co.Boost Price TargetOverweight$8.00 -> $9.00ViewTweet This Rating  Share This Rating on StockTwits
8/20/2014Cowen and CompanyBoost Price Target$14.00ViewTweet This Rating  Share This Rating on StockTwits
7/1/2014Janney Montgomery ScottUpgradeNeutral -> Buy$2.50 -> $5.00ViewTweet This Rating  Share This Rating on StockTwits
7/1/2014Leerink SwannUpgradeMarket Perform -> Outperform$2.50 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
6/30/2014JPMorgan Chase & Co.UpgradeNeutral -> OverweightViewTweet This Rating  Share This Rating on StockTwits
5/6/2014Leerink SwannLower Price Target$3.00 -> $2.50ViewTweet This Rating  Share This Rating on StockTwits
3/4/2014Leerink SwannBoost Price Target$2.50 -> $3.00ViewTweet This Rating  Share This Rating on StockTwits
11/21/2013Janney Montgomery ScottDowngradeBuy -> NeutralViewTweet This Rating  Share This Rating on StockTwits
11/21/2013JPMorgan Chase & Co.DowngradeOverweight -> NeutralViewTweet This Rating  Share This Rating on StockTwits
10/24/2013Leerink SwannDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/18/2013 forward)